Skip to main content
Log in

Recombinant factor VIIa stops bleeding in patients with inhibitors to clotting factors

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Dunn CJ, Spencer CM. Recombinant factor VIIa. BioDrugs 1999 Jul; 12 (1): 71–7

    Article  PubMed  CAS  Google Scholar 

  2. Shapiro AD. Recombinant factor VIIa. A viewpoint. BioDrugs 1999 Jul; 12 (1): 78

    Article  PubMed  CAS  Google Scholar 

  3. ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1999–2000. London: Datapharm Publications Ltd

  4. AHFS Drug Information. Bethesda: American Society of Hospital Pharmacists, 1999: 1275–9, 1285–9

  5. 1999 Mosby’s GenRx. St Louis, Missouri: Mosby-Year Book, Inc., 1998: II–143–4

  6. Mølskov Bech R. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis 1996; 26 Suppl 1: 135–8

    Google Scholar 

  7. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998 Nov; 80: 773–8

    PubMed  CAS  Google Scholar 

  8. Lusher JM. Recombinant factor VIIa (NovoSeven®) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996 Jan; 26 Suppl. 1: 124–30

    PubMed  CAS  Google Scholar 

  9. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treat-ment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia 1998; 4: 790–8

    Article  PubMed  CAS  Google Scholar 

  10. Arkin S, Cooper HA, Hutter JJ, et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Haemostasis 1998; 28: 93–8

    PubMed  CAS  Google Scholar 

  11. Ingerslev J, Freidman D, Gastineau D, et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996 Jan; 26 Suppl. 1: 118–23

    PubMed  CAS  Google Scholar 

  12. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998 Dec; 80: 912–8

    PubMed  CAS  Google Scholar 

  13. Laurian Y, Goudemand J, Négrier C, et al. Use of recombinant activated factor VII as first-line therapy for bleeding episodes in haemophiliacs with factor VIII or IX inhibitors (NOSEPAC study). Blood Coagul Fibrinolysis 1998 Mar; 9 Suppl. 1: S155–6

    Google Scholar 

  14. Ingerslev J, Thykjaer H, Scheibel E. Approaches towards successful home treatment in patients with inhibitors. Eur J Haematol 1998; 61 Suppl. 63: 11–4

    Google Scholar 

  15. Nicolaisen EM. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis 1998 Mar; 9 Suppl. 1: S119–23

    PubMed  CAS  Google Scholar 

  16. Lusher JM. Recombinant factor VIIa. A viewpoint. BioDrugs 1999 Jul; 12 (1): 78–9

    Article  PubMed  CAS  Google Scholar 

  17. Schulman S. Safety, efficacy and lessons from continuous infusion with rFVIIA. Haemophilia 1998 Jul; 4: 564–7

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Recombinant factor VIIa stops bleeding in patients with inhibitors to clotting factors. Drugs Ther. Perspect 15, 1–4 (2000). https://doi.org/10.2165/00042310-200015050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200015050-00001

Keywords

Navigation